Abiomed announced preliminary Q3 results after the market close today.
http://www.nasdaq.com/press-release/abiomed-announces-prelim…
FY 2016 Revenue of $85.8 Million, Up 38% Over Prior Year
Preliminary unaudited U.S. revenue from Impella® products grew 45% to approximately $75.0 million from $51.9 million in the prior fiscal year.
For the third quarter of fiscal 2016, U.S. patient usage grew 45% in comparison with same period of fiscal 2015.
Best,
–Kevin